Dr Bishal Gyawali unpacks the FDA’s decision to deny RP-1 in melanoma, exploring why single-arm data and confounded response rates failed to meet the bar for clinical evidence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results